Daily Courier: Single Column

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

3.375 +0.055 (+1.66%)
Streaming Delayed Price Updated: 10:28 AM EDT, May 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,708,545
Open 3.240
Bid (Size) 3.370 (8,600)
Ask (Size) 3.380 (8,800)
Prev. Close 3.320
Today's Range 3.240 - 3.390
52wk Range 2.800 - 7.180
Shares Outstanding 168,425,907
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
TechMediaBreaks – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) Advances AI Voice-Based Intoxication Detection as Real-Time Diagnostics Market Expands
Via Investor Brand Network
Topics Artificial Intelligence
The Future of Intoxication Detection May Be in Your Voice
Via Investor Brand Network
Topics Artificial Intelligence

Performance

YTD
-19.6%
-19.6%
1 Month
+2.9%
+2.9%
3 Month
-15.2%
-15.2%
6 Month
-25.2%
-25.2%
1 Year
-27.3%
-27.3%

More News

Read More
News headline image
3 Stocks Poised to Disrupt the Healthcare Market by 2030 ↗
Via The Motley Fool
Topics Artificial Intelligence
Recursion Pharmaceuticals (RXRX) Q1 2026 Results: Revenue Miss Overshadows Narrower Net Loss ↗
Via Chartmill
Recursion Pharmaceuticals (NASDAQ:RXRX) Soars on Q4 Earnings Beat ↗
Via Chartmill
News headline image
The Future of Intoxication Detection May Be in Your Voice
From BioMedWire
Via GlobeNewswire
News headline image
Recursion (RXRX) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Recursion Reports First Quarter Financial Results and Provides Business Update
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion Announces Board Transition
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion to Report First Quarter 2026 Business Updates and Financial Results on May 6
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion to Participate in Upcoming Investor Conferences
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Lilly’s $47.8 Billion Bet: Why the Contessa Acquisition Redefines the Future of Medicine
Via MarketMinute
Topics Artificial Intelligence
News headline image
1 Beaten-Down AI Stock to Buy and 1 to Avoid ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Recursion Expands Strategic Partnership with Citeline to Advance Its AI-Enabled ClinTech Platform
From Citeline
Via GlobeNewswire
News headline image
2 AI Healthcare Stocks to Buy Right Now ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Recursion Announces Vicki Goodman, M.D., as Incoming Chief Medical Officer
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Prediction: The "Trough of Disillusionment" Will Create the Best Buying Opportunity for Artificial Intelligence (AI) Stocks in 2026 ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Want $1 Million in Retirement? Invest $10,000 in These 2 AI Stocks and Hold for 10 Years. ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Can This AI Stock Bounce Back in 2026? ↗
Via The Motley Fool
Topics Animal Testing Artificial Intelligence
News headline image
Stocks Under $5 to Watch Now: LRMR, RXRX, NDRA, BTQ, CDIO Watch Now!
Via AB Newswire
Topics Artificial Intelligence Intellectual Property
News headline image
Recursion (RXRX) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Artificial Intelligence Earnings
News headline image
What's Behind The Jump In Recursion Pharmaceuticals Stock? ↗
Via Benzinga
News headline image
RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has ‘Reached An Inflection Point’ ↗
Via Stocktwits
Topics Artificial Intelligence
News headline image
Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion To Be Featured in HighRes’ Lightning Talk at NVIDIA GTC
From Recursion Pharmaceuticals
Via GlobeNewswire

Frequently Asked Questions

Is Recursion Pharmaceuticals, Inc. - Class A Common Stock publicly traded?
Yes, Recursion Pharmaceuticals, Inc. - Class A Common Stock is publicly traded.
What exchange does Recursion Pharmaceuticals, Inc. - Class A Common Stock trade on?
Recursion Pharmaceuticals, Inc. - Class A Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Recursion Pharmaceuticals, Inc. - Class A Common Stock?
The ticker symbol for Recursion Pharmaceuticals, Inc. - Class A Common Stock is RXRX on the Nasdaq Stock Market
What is the current price of Recursion Pharmaceuticals, Inc. - Class A Common Stock?
The current price of Recursion Pharmaceuticals, Inc. - Class A Common Stock is 3.375
When was Recursion Pharmaceuticals, Inc. - Class A Common Stock last traded?
The last trade of Recursion Pharmaceuticals, Inc. - Class A Common Stock was at 05/11/26 10:28 AM ET
What is the market capitalization of Recursion Pharmaceuticals, Inc. - Class A Common Stock?
The market capitalization of Recursion Pharmaceuticals, Inc. - Class A Common Stock is 568.44M
How many shares of Recursion Pharmaceuticals, Inc. - Class A Common Stock are outstanding?
Recursion Pharmaceuticals, Inc. - Class A Common Stock has 568M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

© Copyright 2015, Daily Courier, Kelowna, BC. Powered by BLOX Content Management System from TownNews.com.